Arovella Therapeutics | WA Innovation Ecosystem Navigator
About Arovella Therapeutics
Arovella Therapeutics is a biotechnology company focused on developing invariant Natural Killer T (iNKT) cell therapy platforms to treat cancer. Their lead program, ALA-101, utilizes CAR19-iNKT cells targeting blood cancers, and they are advancing off-the-shelf cell therapies designed to increase accessibility for patients. The company emphasizes patient-centric, data-driven development of unique immunotherapies.
Ecosystem activity
2017
1 milestone
July
Received $50K grant from
Is this your organisation?
Claim this profile to add your story, team and milestones.